Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Topotecan in Relapsed Resistant SCLC
NCT00276276Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2000
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of topotecan in small cell lung cancer (SCLC), sponsored by GSK. Started Nov 2000; status: completed.
02
Drugs
topotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00276276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276276.